Polycythemia vera differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 18: | Line 18: | ||
||[[Polycythemia vera (PV)]] | ||[[Polycythemia vera (PV)]] | ||
| | | | ||
* JAK2 mutation (V617F or exon 12 mutation) | * JAK2 mutation (V617F or exon 12 mutation) in more than 95% of cases | ||
* Autonomous erythrocyte production | * Autonomous erythrocyte production | ||
| | | | ||
| Line 47: | Line 47: | ||
* Clonal proliferation of megakaryocytes | * Clonal proliferation of megakaryocytes | ||
* Excess [[platelet]] production | * Excess [[platelet]] production | ||
* | * Caused by JAK2 mutation in 50% of cases | ||
* Caused by CALR mutation in some cases | |||
| | | | ||
* Stroke-like symptoms | * Stroke-like symptoms | ||
Revision as of 23:28, 28 January 2018
|
Polycythemia vera Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia vera differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Polycythemia vera differential diagnosis |
|
Risk calculators and risk factors for Polycythemia vera differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]
Overview
Polycythemia vera must be differentiated from chronic myelogenous leukemia, essential thrombocythemia, and primary myelofibrosis.[1][2]
Differential Diagnosis
Polycythemia vera must be differentiated from a variety of other conditions.
| Characteristic/Parameter | Etiology | Symptoms | Laboratory abnormalities | Physical examination | Treatment | Other associated abnormalities |
|---|---|---|---|---|---|---|
| Polycythemia vera (PV) |
|
|
|
|
| |
| Essential thrombocythemia (ET) |
|
|
|
|
|
|
| Chronic myeloid leukemia (CML) |
|
|
|
|
|
|
| Primary myelofibrosis (PMF) |
|
|
|
|
References
- ↑ 1.0 1.1 Tefferi A, Barbui T (2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am J Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
- ↑ 2.0 2.1 Sanchez S, Ewton A (2006). "Essential thrombocythemia: a review of diagnostic and pathologic features". Arch Pathol Lab Med. 130 (8): 1144–50. doi:10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2. PMID 16879015.
- ↑ Jabbour E, Kantarjian H (2014). "Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management". Am J Hematol. 89 (5): 547–56. doi:10.1002/ajh.23691. PMID 24729196.